Trial Profile
Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) unlikely to respond to Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Exemestane
- Indications Breast cancer
- Focus Therapeutic Use
- 09 Apr 2021 Status changed from recruiting to discontinued.
- 28 Mar 2012 Actual initiation date (10 Mar 2011) added as reported by European Clinical Trials Database record.
- 28 Mar 2012 Planned end date (10 Sep 2014) added as reported by European Clinical Trials Database record.